A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Aripiprazole will be administered in accordance with the label or Investigator's discretion

Haloperidol will be administered in accordance with the label or Investigator's discretion

Olanzapine will be administered in accordance with the label or Investigator's discretion

Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.

Perphenazine will be administered in accordance with the label or Investigator's discretion

Quetiapine will be administered in accordance with the label or Investigator's discretion

Risperidone tablets 1-6 mg per day will be administered orally.

Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.

Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.